



- 1.) The etiology and morphologic characteristics of
- S. pyogenes.
- 2.) The epidemiology and manifestation
- (signs & symptoms) of S. pyogenes infections.
 - **3.)The extracellular products of S. pyogene, specifically**
 - to include: a. char. Of streptolysin-O b. prop. Of streptolysin-O c. sig. Of the streptolysin-O
 - c. sig. Of the streptolysin-O
 - d. comp. Of strep-O to strep-S e. serologic test of antistreptolysin-O
 - f. Method of antistreptolysin-O titration
 - g. Rapid latex agglutination ASO procedure.





Lancefield Group A

Gram-positive cocci

M protein

Lipotechoic acid

Fimbriae

phagocytosis

M and R antigen



Hanifestation of S. pyogenes Infection

Upper Respiratory Infection:

* RHINORRHEA

- * COUGHING
- * FEVER
- * **VOMITING**
- * ANOREXIA
- * CERVICAL ADENOPATHY
- * STREPTOCOCCAL PHARYNGITIS * PHARYNGEAL ERYTHEMA
- * SCARLET FEVER
- *** SKIN INFECTIONS**













The extracellular products of S. pyogenes

Streptolysin O (SLO) is a bacterial toxin produced by virtually

all strains of S. pyogenes. It is one of two extracellular hemolysins, the

other being streptolysin S (SLS). SLO is released during infection as

indicated by antibody production it. The toxin is a protein with a

molecular weight of approximately 70,000 which, in it's reduced state

brings about the lysis of red and white blood cells..





- oxygen lability
- hemolytically inactive
- Oxygen labile toxins
- -activated by sulfhydryl- Gram positive
- hemolysis of erythrocytes
 - -cardiotoxic
- interstitial myocarditis & systolic arrest in animals
- membrane cholesterol(binding site of slo
- Erythrocyte membrane with ALFAFA saponin or filipin (inhibit the absorption of SLO.

- Antigenic eliciting the formation of antibodies that that effectively neutralize.

Jeance of Antistreptolysin O Reaction

High proportion of patient with streptococcal infection show an antibody response during convalescence, therefore the measurement of serum streptolysin O has become a valuable and reliable indicator of streptococcal infection.

| | with Streptolysin S | | | | | | | | |
|----------------|---------------------|----------|-------|----------|-------|---------|-------------|--------|--|
| | | | | | | | | | |
| | | | | | | | | | |
| 20 | ИО | M | | | NO | | | | |
| 21S | YES | YES | 2,800 | | YES | loosely | leci-b lipo | | |
| | Oxy-sta | Non- ANT | WM | Synthesi | found | peptide | Inhibited | diseas | |
| a | | | | | | | | | |
| ** ** ** | | | | | | | | | |
| | | | | | | | | | |

* Neutralization Test

Taking into account

Infection severity, previous exposure to streptococcal infection, individual ability to respond immunological to the toxin.

•There is no set normal titer for ASO.

- •125 todds units normal in healthy adults.
- •5 to 125 todds units ASO titers flunctuates in children.
- •ASO titer decreases after age 50.

•Rheumatic fever seen during the symptom free period preceeding the attack of the •illness. (300 & 1500 todds units 6 months from the onset of the disease.

Drugs commonly used in treatment of rheumatic fever

Sodium salicylate, Aureum salt & Amino phenazone with phenylbutazone (Irgapyrin).

Penicillin, Aureumycin, hormones, cortisones inhibit the production of the toxin

Nethod 1: Anti streptolysin O Titration

- Allow quantitative analysis of the antibody, this system defines a minimal hemolysis dose of SLO as that amount of toxin that will completely hemolyze 0.5 ml percent suspension of rabbit red blood cells, measured in todds units.
 - PPPS
- saline (.85 percent
- streptolysin O buffer
- Red blood cells
- Test tube



Before reporting results, always ensure that the controls give the expected results.

Method 2: Rapid Latex Agglutination Antistreptolysin O Procedure

• It is based on the principle that if polystyrene latex particles are coated with streptolysin O antigen visible agglutination will be exhibited in the presence of the corresponding antistreptolysin O antibody.

- ASO latex reagent
- 0.9 percent NaCl solution
- Positive control serum
- Negative control serum
- Glass slides with 6 wells

Procedure

- 1. Label a 12 x 75 mm ;test tube.
- 2. Pipette 1 ml of saline into each tube
- **3.** Add 1 drop of patient serum. Mix and invert it several times.
- 4. Label 1 division of the 6 cell slide for positive control, negative
- and respective patient sera
- to be tested.
- 5. Pipette 50 ul of the controls and p[atient sera onto the appropriately labelled cells. Use a fresh pipette for each specimen.
- 6. Add 1 drop of latex reagent to each cell.
- 7. Mix with applicator stick.
- 8. Rotate the slide for exactly 3 minutes.
- 9. Examine immediately with a bright source of direct light.



Interpretation:

•Agglutination- positive-

No-agglutination-negative

If the patient is positive it demonstrate 200 ul or more ASO it should be retested quantitatively.

Patient serum should be prepared as follows:

| dilution | ∐/ml | |
|----------|-------|--|
| ununun | 0/111 | |
| | | |

| 1;30 | 300 | |
|-------|------|--|
| 1;40 | 400 | |
| 1;60 | 600 | |
| 1;80 | 800 | |
| 1;100 | 1000 | |
| | | |





Factors that can cause false-positive reaction. A. bacterial contamination

B. lipemic serum & plasma

Atiter with 200 u/ml or greater may be associated with rheumatic fever or glomerulonephritis.A patient with an elevated titer should be retested over a period of 4 to 6 weeks to plot the course of the titer.